Evidence map›Paper›PMID 37258413›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2023

Inflammatory Biomarkers in Newly Diagnosed Patients With Parkinson Disease and Related Neurodegenerative Disorders.

Camilla Christina Pedersen, Anastasia Ushakova, Ragnhild Eide Skogseth, Guido Alves, Ole-Bjørn Tysnes, Dag Aarsland, Johannes Lange, Jodi Maple-Grødem

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 3 countries.

Camilla Christina PedersenFrom the The Norwegian Centre for Movement Disorders (C.C.P., G.A., J.L., J.M.-G.), Stavanger University Hospital; Department of Chemistry, Bioscience and Environmental Engineering (C.C.P., G.A., J.L., J.M.-G.), University of Stavanger; Section of Biostatistics (A.U.), Department of Research, Stavanger University Hospital; Department of Geriatric Medicine (R.E.S.), Haraldsplass Deaconess Hospital, Bergen; Department of Clinical Medicine (R.E.S., O.-B.T.), University of Bergen; Department of Neurology (G.A.), Stavanger University Hospital; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Centre for Age-Related Medicine (D.A.), Stavanger University Hospital, Norway; and Department of Old Age Psychiatry (D.A.), Institute of Psychiatry, Psychology, and Neuroscience, King's College London, United Kingdom.
Anastasia UshakovaFrom the The Norwegian Centre for Movement Disorders (C.C.P., G.A., J.L., J.M.-G.), Stavanger University Hospital; Department of Chemistry, Bioscience and Environmental Engineering (C.C.P., G.A., J.L., J.M.-G.), University of Stavanger; Section of Biostatistics (A.U.), Department of Research, Stavanger University Hospital; Department of Geriatric Medicine (R.E.S.), Haraldsplass Deaconess Hospital, Bergen; Department of Clinical Medicine (R.E.S., O.-B.T.), University of Bergen; Department of Neurology (G.A.), Stavanger University Hospital; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Centre for Age-Related Medicine (D.A.), Stavanger University Hospital, Norway; and Department of Old Age Psychiatry (D.A.), Institute of Psychiatry, Psychology, and Neuroscience, King's College London, United Kingdom.
Ragnhild Eide SkogsethFrom the The Norwegian Centre for Movement Disorders (C.C.P., G.A., J.L., J.M.-G.), Stavanger University Hospital; Department of Chemistry, Bioscience and Environmental Engineering (C.C.P., G.A., J.L., J.M.-G.), University of Stavanger; Section of Biostatistics (A.U.), Department of Research, Stavanger University Hospital; Department of Geriatric Medicine (R.E.S.), Haraldsplass Deaconess Hospital, Bergen; Department of Clinical Medicine (R.E.S., O.-B.T.), University of Bergen; Department of Neurology (G.A.), Stavanger University Hospital; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Centre for Age-Related Medicine (D.A.), Stavanger University Hospital, Norway; and Department of Old Age Psychiatry (D.A.), Institute of Psychiatry, Psychology, and Neuroscience, King's College London, United Kingdom.
Guido AlvesFrom the The Norwegian Centre for Movement Disorders (C.C.P., G.A., J.L., J.M.-G.), Stavanger University Hospital; Department of Chemistry, Bioscience and Environmental Engineering (C.C.P., G.A., J.L., J.M.-G.), University of Stavanger; Section of Biostatistics (A.U.), Department of Research, Stavanger University Hospital; Department of Geriatric Medicine (R.E.S.), Haraldsplass Deaconess Hospital, Bergen; Department of Clinical Medicine (R.E.S., O.-B.T.), University of Bergen; Department of Neurology (G.A.), Stavanger University Hospital; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Centre for Age-Related Medicine (D.A.), Stavanger University Hospital, Norway; and Department of Old Age Psychiatry (D.A.), Institute of Psychiatry, Psychology, and Neuroscience, King's College London, United Kingdom.
Ole-Bjørn TysnesFrom the The Norwegian Centre for Movement Disorders (C.C.P., G.A., J.L., J.M.-G.), Stavanger University Hospital; Department of Chemistry, Bioscience and Environmental Engineering (C.C.P., G.A., J.L., J.M.-G.), University of Stavanger; Section of Biostatistics (A.U.), Department of Research, Stavanger University Hospital; Department of Geriatric Medicine (R.E.S.), Haraldsplass Deaconess Hospital, Bergen; Department of Clinical Medicine (R.E.S., O.-B.T.), University of Bergen; Department of Neurology (G.A.), Stavanger University Hospital; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Centre for Age-Related Medicine (D.A.), Stavanger University Hospital, Norway; and Department of Old Age Psychiatry (D.A.), Institute of Psychiatry, Psychology, and Neuroscience, King's College London, United Kingdom.
Dag AarslandFrom the The Norwegian Centre for Movement Disorders (C.C.P., G.A., J.L., J.M.-G.), Stavanger University Hospital; Department of Chemistry, Bioscience and Environmental Engineering (C.C.P., G.A., J.L., J.M.-G.), University of Stavanger; Section of Biostatistics (A.U.), Department of Research, Stavanger University Hospital; Department of Geriatric Medicine (R.E.S.), Haraldsplass Deaconess Hospital, Bergen; Department of Clinical Medicine (R.E.S., O.-B.T.), University of Bergen; Department of Neurology (G.A.), Stavanger University Hospital; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Centre for Age-Related Medicine (D.A.), Stavanger University Hospital, Norway; and Department of Old Age Psychiatry (D.A.), Institute of Psychiatry, Psychology, and Neuroscience, King's College London, United Kingdom.
Johannes LangeFrom the The Norwegian Centre for Movement Disorders (C.C.P., G.A., J.L., J.M.-G.), Stavanger University Hospital; Department of Chemistry, Bioscience and Environmental Engineering (C.C.P., G.A., J.L., J.M.-G.), University of Stavanger; Section of Biostatistics (A.U.), Department of Research, Stavanger University Hospital; Department of Geriatric Medicine (R.E.S.), Haraldsplass Deaconess Hospital, Bergen; Department of Clinical Medicine (R.E.S., O.-B.T.), University of Bergen; Department of Neurology (G.A.), Stavanger University Hospital; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Centre for Age-Related Medicine (D.A.), Stavanger University Hospital, Norway; and Department of Old Age Psychiatry (D.A.), Institute of Psychiatry, Psychology, and Neuroscience, King's College London, United Kingdom.ORCID 0000-0003-0604-4891
Jodi Maple-GrødemFrom the The Norwegian Centre for Movement Disorders (C.C.P., G.A., J.L., J.M.-G.), Stavanger University Hospital; Department of Chemistry, Bioscience and Environmental Engineering (C.C.P., G.A., J.L., J.M.-G.), University of Stavanger; Section of Biostatistics (A.U.), Department of Research, Stavanger University Hospital; Department of Geriatric Medicine (R.E.S.), Haraldsplass Deaconess Hospital, Bergen; Department of Clinical Medicine (R.E.S., O.-B.T.), University of Bergen; Department of Neurology (G.A.), Stavanger University Hospital; Department of Neurology (O.-B.T.), Haukeland University Hospital, Bergen; Centre for Age-Related Medicine (D.A.), Stavanger University Hospital, Norway; and Department of Old Age Psychiatry (D.A.), Institute of Psychiatry, Psychology, and Neuroscience, King's College London, United Kingdom. jodi.maple@uis.no.
King's College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesNeuroinflammation contributes to Parkinson disease (PD) pathology, and inflammatory biomarkers may aid in PD diagnosis. Proximity extension assay (PEA) technology is a promising method for multiplex analysis of inflammatory markers. Neuroinflammation also plays a role in related neurodegenerative diseases, such as dementia with Lewy bodies (DLB) and Alzheimer disease (AD). The aim of this work was to assess the value of inflammatory biomarkers in newly diagnosed patients with PD and in patients with DLB and AD.

methodsPatients from the Norwegian ParkWest and Dementia Study of Western Norway longitudinal cohorts (PD, n = 120; DLB, n = 15; AD, n = 27) and 44 normal controls were included in this study. A PEA inflammation panel of 92 biomarkers was measured in the CSF. Disease-associated biomarkers were identified using elastic net (EN) analysis. We assessed the discriminatory power of disease-associated biomarkers using receiver operating characteristic (ROC) curve analysis and estimated the optimism-adjusted area under the curve (AUC) using the bootstrapping method.

resultsEN analysis identified 9 PEA inflammatory biomarkers (ADA, CCL23, CD5, CD8A, CDCP1, FGF-19, IL-18R1, IL-6, and MCP-2) associated with PD. Seven of the 9 biomarkers were included in a diagnostic panel, which was able to discriminate between those with PD and controls (optimism-adjusted AUC 0.82). Our 7-biomarker PD panel was also able to distinguish PD from DLB and from AD. In addition, 4 inflammatory biomarkers were associated with AD and included in a panel, which could distinguish those with AD from controls (optimism-adjusted AUC 0.87). Our 4-biomarker AD panel was also able to distinguish AD from DLB and from PD. DISCUSSION: In our exploratory study, we identified a 7-biomarker panel for PD and a 4-biomarker panel for AD. Our findings indicate potential inflammation-related biomarker candidates that could contribute toward PD-specific and AD-specific diagnostic panels, which should be further explored in other larger cohorts.

Indexed as

Alzheimer DiseaseLewy Body DiseaseNeurodegenerative DiseasesParkinson DiseaseAntigens, NeoplasmBiomarkersCell Adhesion MoleculesHumansNeuroinflammatory Diseasestau ProteinsAntigens, NeoplasmBiomarkersCDCP1 protein, humanCell Adhesion Moleculestau Proteins

Identifiers

PMID37258413
PMCPMC10231912
OpenAlexW4378901988

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.